Diagnostic technology has evolved at a rapid pace over the past decade, owing to significant breakthroughs in research and development. Within the HIV/AIDS immunoassay diagnostics market landscape, the demand for automated clinical laboratory has paved the way for efficient and reliable antibodies and antigen identification techniques. Despite significant progress, the human immunodeficiency virus (HIV) continues to be a major global health problem and a medical challenge. Some of the most effective and critical HIV management strategies include antiretroviral therapy (ART) initiation, early diagnosis, and assessment of the viral load.
HIV diagnostic tests offer two solutions - detection of virus molecules (p24 antigen and HIV RNA) and/or different antibodies to the virus. HIV/AIDS immunoassays, in particular, are used to detect antibodies and p24 antigen. Due to the growing need to curb HIV/AIDS and other types of HIV infections, the demand for efficient diagnostic techniques has increased significantly worldwide. The global HIV/AIDS immunoassay diagnostics market is expected to expand from ~US$ 570 Mn in 2019 to a value of ~US$ 870 Mn by 2027.
Around 38 million individuals across the world had HIV in 2018 of which, approximately 36 million were adults. Furthermore, ~1.7 million new HIV cases were registered in 2018 and the numbers continue to grow, especially in the sub-Saharan region and low-income economies. Key participants involved in the HIV/AIDS immunoassay diagnostics market are focusing on simplifying and improving the effectiveness of HIV diagnostics.
Antibody screening tests including the enzyme linked immunosorbent assay (ELISA) are predominantly used to measure antibodies in blood. This test is generally the first test ordered by healthcare professionals to detect HIV antigens in the blood. Traditionally, enzyme-linked immunosorbent assays are complex, expensive, and often require a skilled professional. However, as ELISA is easier and safer than radioimmunoassay (RIA); its adoption will continue to grow at a steady pace over the forecast period (2019-2027). Thus, the ELISA segment is projected to create an incremental opportunity of ~US$ 112 Mn between the stipulated timeframe of the study. The diagnostic results using ELISA could take a few days, which has led to the need for rapid testing techniques.
Despite steady growth of the ELISA segment, the chemiluminescent immunoassay segment (CLIA) segment is expected to hold a larger share of the HIV/AIDS immunoassay diagnostics market, in terms of value. By the end of 2027, the CLIA segment is likely to account for ~48% of the total share of the HIV/AIDS immunoassay diagnostics market and witness a CAGR of ~6% during the forecast period. Over the past few years, CLIA has gained significant popularity in various sectors, including clinical diagnosis, life sciences, pharmaceutical analysis, and environmental monitoring, among others due to factors such as optimum specificity, easy-to-use equipment, wider linear range, and high sensitivity. Techniques based on chemiluminescent are increasingly being used for clinical analysis and several biomedical research activities.
Presently, major players operating in the global HIV/AIDS immunoassay diagnostics market are striving to offer effective, reliable, cost-effective HIV/AIDS immunoassay diagnostics. In addition, increasing prevalence of HIV/AIDS and HIV infections worldwide have prompted market participants to provide new and improved HIV testing technologies. Companies are focusing on improving patient outcomes and minimizing disease transmission, which requires reliable and accurate clinical laboratory testing. For instance, Siemens Healthineers launched the Atellica ® IM and ADVIA Centaur ® HIV Combo to improve the detection of HIV infections. The entry of new technologies, including the third-generation enzyme immunoassay, which detects IgM and IgG antibodies and fourth-generation enzyme immunoassay that detect HIV p24 and HIV antibodies, are some of the most recent groundbreaking developments in the global HIV/AIDS immunoassay market.
Moreover, product development is likely to fuel the global HIV/AIDS immunoassay market, as companies are seeking approvals from the U.S. FDA. For instance, Shenzen New Industries Biomedical Engineering Co., Ltd (SNIBE) became the first China-based company in the HIV/AIDS immunoassay diagnostics market to receive the approval from the U.S. FDA for the newly developed automated immunoassay analyzer.
Analysts’ Viewpoint
Companies operating in the HIV/AIDS immunoassay diagnostics market should focus on improving the effectiveness of their HIV diagnosis techniques. In addition, clinical and laboratory trials of newer technologies will play an imperative role in driving the growth of the HIV/AIDS immunoassay diagnostics market. Despite a healthy competition from the ELISA segment, CLIA is likely to retain its dominance, in terms of adoption, during the forecast period. Developments in the CLIA technology, including the flow-injection CLIA technology, will address problems associated with existing alternatives.
Companies Mentioned in Report
Global HIV/AIDS Immunoassay Diagnostics Market – Segmentation
|
Product |
Analyzers Kits & Reagents |
|
Technology |
Enzyme-linked Immunosorbent Assay (ELISA) Chemiluminescence Immunoassay (CLIA) Others |
|
End User |
Hospitals Diagnostic Laboratories Blood Banks Others |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
HIV/AIDS immunoassay diagnostics market to reach a valuation of ~US$ 870 Mn by 2027
HIV/AIDS immunoassay diagnostics market is projected to expand at a CAGR of ~5% from 2019 to 2027
HIV/AIDS immunoassay diagnostics market is driven by rise in prevalence of sexually transmitted diseases and HIV infected population
The kits & reagents segment held a major share of the global HIV/AIDS immunoassay diagnostics market and the trend is anticipated to continue during the forecast period
Key players in the global HIV/AIDS immunoassay diagnostics market include F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, DiaSorin S.p.A., Abbott Laboratories
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global HIV/AIDS Immunoassay Diagnostics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Technological Advancements
5.2. Key Industry Developments
5.3. Epidemiology Analysis
5.4. Number of HIV/AIDS Immunoassay Diagnostics Tests, by Region
5.5. Pricing Analysis
6. Global HIV/AIDS Immunoassay Diagnostics Market Value and Forecast, by Product
6.1. Introduction & Definition
6.2. Global HIV/AIDS Immunoassay Diagnostics Market Value Forecast, by Product, 2017–2027
6.2.1. Analyzers
6.2.2. Kits & Reagents
6.3. Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product
7. Global HIV/AIDS Immunoassay Diagnostics Market Value and Forecast, by Technology
7.1. Introduction
7.2. Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
7.2.1. ELISA
7.2.2. CLIA
7.2.3. Others
7.3. Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology
8. Global HIV/AIDS Immunoassay Diagnostics Market Value and Forecast, by End User
8.1. Introduction
8.2. Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
8.2.3. Blood Banks
8.2.4. Others
8.3. Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User
9. Global HIV/AIDS Immunoassay Diagnostics Market Value and Forecast, by Region
9.1. Introduction
9.2. Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Region
10. North America HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
10.2.1. Analyzers
10.2.2. Kits & Reagents
10.3. North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
10.3.1. ELISA
10.3.2. CLIA
10.3.3. Others
10.4. North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Blood Banks
10.4.4. Others
10.5. North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Technology
10.6.3. By End User
10.6.4. By Country
11. Europe HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
11.2.1. Analyzers
11.2.2. Kits & Reagents
11.3. Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
11.3.1. ELISA
11.3.2. CLIA
11.3.3. Others
11.4. Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Blood Banks
11.4.4. Others
11.5. Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Rest of Europe
11.6. Europe HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Technology
11.6.3. By End User
11.6.4. By Country/Sub-region
12. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
12.2.1. Analyzers
12.2.2. Kits & Reagents
12.3. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
12.3.1. ELISA
12.3.2. CLIA
12.3.3. Others
12.4. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
12.4.1. Hospitals
12.4.2. Diagnostic Laboratories
12.4.3. Blood Banks
12.4.4. Others
12.5. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Technology
12.6.3. By End User
12.6.4. By Country/Sub-region
13. Latin America HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
13.2.1. Analyzers
13.2.2. Kits & Reagents
13.3. Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
13.3.1. ELISA
13.3.2. CLIA
13.3.3. Others
13.4. Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
13.4.1. Hospitals
13.4.2. Diagnostic Laboratories
13.4.3. Blood Banks
13.4.4. Others
13.5. Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Technology
13.6.3. By End User
13.6.4. By Country/Sub-region
14. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
14.2.1. Analyzers
14.2.2. Kits & Reagents
14.3. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
14.3.1. ELISA
14.3.2. CLIA
14.3.3. Others
14.4. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
14.4.1. Hospitals
14.4.2. Diagnostic Laboratories
14.4.3. Blood Banks
14.4.4. Others
14.5. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Technology
14.6.3. By End User
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Global HIV/AIDS Immunoassay Diagnostics Market Share Analysis, by Company (2018)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Bio-Rad Laboratories, Inc.
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Siemens Healthineers AG.
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. DiaSorin S.p.A.
15.3.4.1. Company Description
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Abbott Laboratories
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Ortho Clinical Diagnostics (a part of Carlyle Group)
15.3.6.1. Company Description
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Shenzhen New Industries Biomedical Engineering Co., Ltd.
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. bioMérieux SA
15.3.8.1. Company Description
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Fujirebio (Miraca Group)
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Financial Overview
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
List of Tables
Table 01: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 02: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 03: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 04: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 05: North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 06: North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 07: North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 08: North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 09: Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 10: Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 11: Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 12: Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 13: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 15: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 16: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 17: Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 19: Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 20: Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 21: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 23: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 24: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast, by End User, 2017–2027
List of Figures
Figure 01: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027
Figure 02: Global HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027
Figure 03: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018
Figure 04: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018
Figure 05: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018
Figure 06: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Region, 2018
Figure 07: HIV/AIDS Immunoassay Diagnostics Market – Mergers, Acquisitions, Collaborations, Partnerships & New Product Launch
Figure 08: Technological Advancements
Figure 09: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 10: Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 11: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Analyzers, 2017–2027
Figure 12: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Kits & Reagents, 2017–2027
Figure 13: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 14: Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 15: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by ELISA, 2017–2027
Figure 16: Global Ne HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CLIA, 2017–2027
Figure 17: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 18: Global HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 19: Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 20: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 21: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Laboratories, 2017–2027
Figure 22: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks, 2017–2027
Figure 23: Global HIV/AIDS Immunoassay Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 24: Global HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Region, 2018 and 2027
Figure 25: Global HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Region, 2019–2027
Figure 26: North America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 27: North America HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 28: North America HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Country, 2019–2027
Figure 29: North America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 30: North America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 31: North America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 32: North America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 33: North America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 34: North America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 35: Europe HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 36: Europe HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 37: Europe HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 38: Europe HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 39: Europe HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 40: Europe HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 41: Europe HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 42: Europe HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 43: Europe HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 44: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 45: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 47: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 48: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 49: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 50: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 51: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 52: Asia Pacific HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 53: Latin America HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 54: Latin America HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 55: Latin America HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 56: Latin America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 57: Latin America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 58: Latin America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 59: Latin America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 60: Latin America HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 61: Latin America HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 62: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 63: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 64: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 65: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Product, 2018 and 2027
Figure 66: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Product, 2019–2027
Figure 67: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by Technology, 2018 and 2027
Figure 68: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by Technology, 2019–2027
Figure 69: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Value Share (%), by End User, 2018 and 2027
Figure 70: Middle East & Africa HIV/AIDS Immunoassay Diagnostics Market Attractiveness, by End User, 2019–2027
Figure 71: Global HIV/AIDS Immunoassay Diagnostics Market Share Analysis, by Company, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
HIV/AIDS Immunoassay Diagnostics Market
